Artificial Intelligence In Drug Discovery And Pharmacology

1 Vaishali Kailas Gaikwad, 2 Snehal Trimbak Daud , 3 Dr.DK.Vir , 4 Komal Karabhari Gadekar ,5 Pooja Prabhakar Gadekar
1,4,5 Student,2 Associate professor,3 principle
Department of pharmaceutical sciences and technology
Shree Goraksh College of pharmacy and research centre Khamgaon , Chhatrapati Sambhajinagar, India

Abstract:-Artificial Intelligence (AI) is revolutionizing the field of drug discovery and pharmacology by enhancing the speed, accuracy, and efficiency of research and development processes. AI algorithms, particularly machine learning and deep learning models, are used to analyze complex biological data, predict molecular interactions, and identify potential drug candidates much faster than traditional laboratory methods. In pharmacology, AI helps in understanding drug mechanisms, optimizing dosage, and predicting adverse drug reactions. This integration of AI reduces the time and cost of drug development, enabling faster delivery of effective medicines to patients. However, challenges such as data privacy, model transparency, and the need for regulatory approval remain critical. Overall, AI holds immense potential to transform modern healthcare through innovation in drug discovery and pharmacological research.

Index Terms Artificial Intelligence (AI), Machine Learning (ML),Deep Learning (DL) ,Drug Discovery, Pharmacology,Drug Design, Virtual Screening,ADMET Prediction, Drug Repurposing, Precision Medicine

Introduction:-

Drug development is traditionally labor-intensive, requiring extensive screening, preclinical validation, and multi-phase clinical trials. Reports indicate that the cost of developing a single new drug has continued to rise, while clinical failure rates remain around 90%. These challenges have created strong motivation for adopting computational techniques that can reduce uncertainty and shorten development cycles.

Artificial intelligence has emerged as one of the most transformative technologies influencing scientific research, healthcare, and industry. In pharmaceutical science, AI methods—including deep learning, generative modeling, and natural language processing—are increasingly integrated into drug design, formulation, and real-world clinical decision support. This paper reviews recent evolutionary trends, benchmarks, and applications of AI within the pharmaceutical domain



Fig – 01 stages of drug discovery

- Drug development is costly ($161M–$4.5B) with ~90% clinical trial failure.
- STAR framework improves drug efficacy, safety, and reduces late-stage failures.
- AI speeds discovery by analyzing data, predicting drug properties, and optimizing candidates.
- Modern drug discovery is multi-stage, from compound isolation to clinical testing.

Fig:-02 phase of clinical trials

Methods

This review incorporates information from peer-reviewed articles, scientific reports, benchmark studies, and domain-specific analyses published between 2018 and 2025. Sources include journals within drug discovery, pharmacogenomics, computational chemistry, pharmacoepidemiology, and pharmaceutical sciences. Key themes—AI applications, challenges, technological advances, and future prospects—were synthesized to construct a comprehensive overview.

Litrature survey

- Domain-Specific Language Model Pretraining (Biochemical NLP):

  Developing DSLMs pretrained on biochemical corpora greatly improves entity recognition, relation extraction, and knowledge discovery, outperforming general-purpose NLP models



Fig:-03Domain specific language model pretraining(Biochemical (NPL)

- Therapeutics Data Commons (TDC):
  Provides standardized, curated datasets and benchmarks for drug discovery tasks, enabling reproducibility and fair model comparison across the pharmaceutical AI community.



Fig:-04 Therapeutic Data commons (TDC)

- BioBERT (Biomedical BERT):
  A domain-adapted version of BERT pretrained on biomedical literature, achieving superior



performance in biomedical NLP tasks such as NER, relation extraction, and QA.

Fig:-05 BioBERT

- PharmaBench:
  Enhances ADMET prediction by integrating molecular data with textual biomedical knowledge, demonstrating the effectiveness of LLMs in real-world pharmacological property prediction.



Fig:-06 Pharmabech

- MoleculeNet:
  A comprehensive benchmarking suite for molecular machine learning, offering standardized datasets, splits, and metrics—showing strong performance for graph neural networks in molecular property prediction.



Fig:- 07 Molecule Net

- AI for DDR1 Kinase Inhibitor Discovery:
  Demonstrates AI-driven drug design by generating and experimentally validating potent DDR1 kinase inhibitors, significantly reducing the time and cost of traditional Discovery pipelines.

Generative AI in drug discovery

- Non-autoregressive: GANs, VAEs; generate molecular graphs in one step.
- Autoregressive: RNNs; generate sequences like SMILES.
- Advanced frameworks: Transformers, LLMs, CLMs.
- RL & TL: Optimize molecule properties and fine-tune models for specific targets.
- GNNs/GCNs/CNNs: Analyze molecular graphs and images



Classification of AI in Drug Discovery

❖ **Machine Learning (ML):**

- Improves drug classification by analyzing pharmacodynamic and pharmacokinetic properties.
- Reinforcement learning accelerates discovery; transfer learning predicts patient responses.

❖ **Deep Learning (DL):**

- Uses multi-layer neural networks to learn from large datasets.
- Enhances prediction, design, and optimization of drug

❖ Role of AI in Drug Discovery

1. Drug Design:

Predicts 3D protein structures (e.g., AlphaFold).
Predicts drug–protein interactions and biological activity.
Supports de novo drug design.

2. Polypharmacology:
3. Designs drugs for specific targets or multiple targets simultaneously.
4. Chemical Synthesis:

Predicts reaction yield and retrosynthesis pathways.
Optimizes synthetic routes and studies reaction mechanism

5. Drug Repurposing:

Identifies new therapeutic targets and potential uses for existing drugs.

6. Drug Screening:

Predicts toxicity, bioactivity, physicochemical properties, and target cell types

❖ Applications of AI

- Target Identification & Validation: Rapidly identifies drug targets using complex biological datasets.
- Drug Screening & Lead Discovery: Uses virtual screening and QSAR models to filter compounds efficiently.
- Drug Optimization & Design: Optimizes chemical properties and predicts target interactions.
- Preclinical & Clinical Development: Predicts ADME/PK-PD properties, streamlining development pipelines.



❖ AI in Pharmacology

- Drug Discovery & Development: Identifies candidates, predicts interactions, optimizes leads.
- PK/PD Prediction: Models absorption, distribution, metabolism, and excretion.
- Clinical Pharmacology & Real-World Data Mining: Mines patient data for therapy personalization.
- Pharmacovigilance: Detects adverse drug reactions and handles large datasets.
- Benefits & Strengths of AI
    - Efficient handling of large, complex datasets.
    - Faster hypothesis generation and candidate screening, reducing time and cost.
    - Improved predictive power for PK/PD, drug-target interactions, and toxicity.
    - Enables personalized medicine by tailoring therapies to patient-specific characteristics.

❖ Future perspective

- AI will accelerate drug discovery by identifying targets, predicting interactions, and designing new molecules.
- Clinical trials will improve through AI-guided patient selection, dose optimisation, and advanced PK/PD modelling.
- Personalised medicine will expand as AI integrates genetic and clinical data to predict drug response and minimise risks.

- AI will optimise drug formulation, manufacturing processes, and quality control through real-time monitoring and prediction.
- Drug repurposing and virtual screening will become faster and more efficient with AI-driven in silico evaluation.
- Future advances will integrate AI with quantum computing, federated learning, and cross-disciplinary collaboration.

Conclusion: AI enables efficient analysis of large, complex datasets such as chemical, biological, and patient data. It accelerates hypothesis generation and candidate screening, reducing time and cost in early drug development. With improved predictive modeling for PK/PD, drug-target interactions, and toxicity, AI also supports personalized medicine by tailoring therapies to individual patient needs.

Reference:

1. Natesh Singh, et.al, discovery and development introduction to the general public and patient groups, Journal of Front. Drug Discovery, 2023; vol.(3) .
2. Michael Schlander. Et.al, How much does it cost to research and develop a new drug a systematic review and assessment, Journal of Pharmacogenomics, 2021; 39(11) .
3. Duxin sun, et.al, Why 90% of clinical drug development fails and how to improve it?, Journal of Acta Pharma Sin B. , 2022 ; 12(7); 3049-3062 .
4. Darrell M.west and John R.Allen ,How Artificial intelligence is transformative the world,April 24,2018
5. Ross Grutezemacher et.al ,The transformative potential of Artificial intelligence Journal computer science 2021;vol.1
6. Noumsn Ali et.al, Deep learning and artificial intelligence for drug discovery, application, challenges, and future perspective.Journal Discover applied since,2025;vol.7, article no.533
7. GU. Y., Thin, T. N., Cheng, H., Lucas, P., Usumyama, N., Liu, X., … & Poon, N. H. (2021). Domain-specific language model pretraining for biochemical natural language processing. ACM Transactions on Computing for Healthcare, 3(4), 1-23.
8. Huang, K., Fu, T., Glass, L. M., Zitnik, M., Hao, C., Sun, Y., … & Xie, L. (2021). Therapeutics data commons: iml dataset & tasks for drug discovery & development. Nature communications, 12(1), 1-13.
9. Lee, J., Yoon, W., Kim, S., Kim, D., Kim, S., Go, C. H., & Kang, J. (2020). BioBERT: A pre-trained biomedical language representation model for biomedical text mining. Bioinformatics, 36(4), 1234-1241.
10. Niu, Z., Xiao, X., & Chen, H. (2024). PharmaBench: Enhancing ADMET benchmark with large language models. Scientific reports, 14(1), 987.
11. W.U. Ramsunder B, Fienberg E N, Grams J, Gaminess S, Puppy A S, Pande V. (2018). Molecules :-- A benchmark for molecular machine learning chemical Science \mathbf{9(2) 513\-530}
12. Zhavaronkov A, Ivanenkov Y A, Alipers A, Neselov I S, Aladinskyy I, Kadurin A (2019) DL enables rupid identify of patent DDR1 kines inhibits. Nature Biotechnology 37(4) 1038-1020
13. Amit Gangwal,Azim Ansari et,al Generative artificial intelligence; basic framework,recent advances, challenges and opportunities, journal Experimental pharmacology and discovery .2024,bol.15
14. Veer patel,Mana shah, Artificial intelligence and machine learning in drug discovery and development; Department of of chemical engineering 2022(3) vol,2
15. Bing Li,kan Tan et.al A comprehensive review of artificial intelligence for pharmocogy research;sec.computational Genomics,2024.vol,15
16. Maaike van der Lee et,al Artificial intelligence in pharmacology research and practice . Journal ASCPT;2022;16(1)
17. Alexandr A kalinin et,al Deep learning in Pharmacogenomics; form gene regulation to patient stratification.Journal Pharmacogenomics; 2018 ;19(7);629-650
18. Ayesha sultana, Rahath Maseera et,al.Emerging of artificial intelligence and technology in pharmaceutical review.Journal of pharmaceutical science 2023;(65)

19. Kazi Asraf Ali,SK Mohin,et.al, Influence of artificial intelligence in modern pharmaceutical formulations and drug development; future journal of pharmaceutical science ;(53),2024
20. Saad S Alqatani, Santosh Joseph Menachery ,et.al, artificial intelligence in clinic pharmacy -A systematic review of current scenario and future perspective; PMC; Oct 2025;21;11
21. Chen Fu, Qiuchen Chen The future of pharmaceutical; Artificial intelligence in drug discovery and development . Journal of pharmaceutical Analysis;2025;vol.15(8)101248
22. Maurizio Sessa, Abdul Rauf khan,et,al Artificial intelligence in pharmacoepidemiology;A part-1 Overview of knowledge discovery Techniques in Artificial intelligence ;front.pharmacol.,2020 vol.11
23. Yuyun Wu, Lijing Ma, xinyi Li,etc,al.The role of artificial intelligence in drug screening, drug design, and clinical trials; front. Pharmacol.,2024.vol,15
24. Negar Mottaghi, Mohammad Soltany, advancement and application of artificial intelligence in pharmaceutical science;A comprehensive review; Iranian journal of pharmaceutical research 23(1)2024

International Research Journal
IJNRD
Research Through Innovation